PHAXIAM Therapeutics S.A.
$3.10▼ 5.20%($-0.17)
TickerSpark Score
53/100
▌ Mixed
87
Valuation
65
Profitability
15
Growth
68
Health
30
Momentum
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHXM research report →
52-Week Range6% of range
Low
$2.50
Current
$3.10
High
$13.00
Company Overviewwww.erytech.com
About the company
PHAXIAM Therapeutics S. A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.
- CEO
- Eric Soyer
- IPO
- 2017
- Employees
- 49
- HQ
- Lyon, FR
Price Chart
-58.94% · this period
Valuation
- Market Cap
- $19.86M
- P/E
- -0.02
- P/S
- 0.76
- P/B
- 0.02
- EV/EBITDA
- -0.17
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -1784.31%
- Net Margin
- -1771.34%
- ROE
- -95.68%
- ROIC
- -56.27%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-23,488,000 · -10247.14%
- EPS
- $-4.62 · -4520.00%
- Op Income
- $-25,417,000
- FCF YoY
- 22.81%
Performance & Tape
- 52W High
- $13.00
- 52W Low
- $2.50
- 50D MA
- $3.88
- 200D MA
- $5.17
- Beta
- 1.80
- Avg Volume
- 1.89K
Get TickerSpark's AI analysis on PHXM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Coverage · PHXM
Our PHXM coverage
Recent articles, reports, and earnings notes.
On-Demand Research
No research on PHXM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PHXM report →Internal Compare
Similar companies
Peers in the same neighborhood.